DK3244909T3 - Proteasominhibitorer til at behandle en lidelse relateret til en akkumulering af ikke-degraderet unormalt protein eller en cancer - Google Patents
Proteasominhibitorer til at behandle en lidelse relateret til en akkumulering af ikke-degraderet unormalt protein eller en cancer Download PDFInfo
- Publication number
- DK3244909T3 DK3244909T3 DK16700619.6T DK16700619T DK3244909T3 DK 3244909 T3 DK3244909 T3 DK 3244909T3 DK 16700619 T DK16700619 T DK 16700619T DK 3244909 T3 DK3244909 T3 DK 3244909T3
- Authority
- DK
- Denmark
- Prior art keywords
- proteasomin
- degradated
- inhibitors
- cancer
- accumulation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 title 1
- 238000009825 accumulation Methods 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305026 | 2015-01-14 | ||
| PCT/EP2016/050678 WO2016113357A1 (en) | 2015-01-14 | 2016-01-14 | Proteasome inhibitors for treating a disorder related to an accumulation of non-degraded abnormal protein or a cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3244909T3 true DK3244909T3 (da) | 2020-01-13 |
Family
ID=52434704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16700619.6T DK3244909T3 (da) | 2015-01-14 | 2016-01-14 | Proteasominhibitorer til at behandle en lidelse relateret til en akkumulering af ikke-degraderet unormalt protein eller en cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20170368134A1 (da) |
| EP (1) | EP3244909B1 (da) |
| JP (2) | JP2018503632A (da) |
| CN (1) | CN107405378B (da) |
| AU (1) | AU2016208001B2 (da) |
| BR (1) | BR112017015059A2 (da) |
| CA (1) | CA2972740A1 (da) |
| CY (1) | CY1122583T1 (da) |
| DK (1) | DK3244909T3 (da) |
| ES (1) | ES2764452T3 (da) |
| HU (1) | HUE047603T2 (da) |
| PL (1) | PL3244909T3 (da) |
| PT (1) | PT3244909T (da) |
| SG (1) | SG11201705108TA (da) |
| WO (1) | WO2016113357A1 (da) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US20150166985A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting von willebrand factor point mutations |
| EP2908137A1 (en) | 2014-02-14 | 2015-08-19 | Institut Pasteur | Methods for in vitro investigating mitochondrial replication dysfunction in a biological sample, kits and uses thereof, therapeutic methods against progeroid-like syndromes or symptomes and screening method for identifying particular protease inhibitor(s) and/or nitroso-redox stress scavenger compound(s) |
| CA2956224A1 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| IL294014B2 (en) | 2015-10-23 | 2024-07-01 | Harvard College | Nucleobase editors and uses thereof |
| SG11201900907YA (en) | 2016-08-03 | 2019-02-27 | Harvard College | Adenosine nucleobase editors and uses thereof |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| US11141389B2 (en) | 2017-01-31 | 2021-10-12 | The Board Of Trustees Of The Leland Stanford Junior University | Agents that inhibit NGLY1 and methods of use thereof |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| IL269458B2 (en) | 2017-03-23 | 2024-02-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| AU2018352592C1 (en) | 2017-10-16 | 2025-09-25 | Beam Therapeutics, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND PROCEDURES FOR PREDICTING REPAIR RESULTS IN GENE ENGINEERING |
| EP3797160A1 (en) | 2018-05-23 | 2021-03-31 | The Broad Institute Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| US20240173430A1 (en) * | 2018-09-05 | 2024-05-30 | The Broad Institute, Inc. | Base editing for treating hutchinson-gilford progeria syndrome |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| GB2601618B (en) | 2019-03-19 | 2024-11-06 | Broad Inst Inc | Methods and compositions for editing nucleotide sequences |
| AU2020272861A1 (en) * | 2019-04-10 | 2021-10-07 | Dana-Farber Cancer Institute, Inc. | Degraders of fibroblast growth factor receptor 2 (FGFR2) |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2021072328A1 (en) | 2019-10-10 | 2021-04-15 | The Broad Institute, Inc. | Methods and compositions for prime editing rna |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| CN112007160A (zh) * | 2020-08-17 | 2020-12-01 | 暨南大学 | 蛋白酶体抑制剂在抗癌药物中的应用 |
| EP4251636A1 (en) * | 2020-11-24 | 2023-10-04 | Progelife | Compounds for treating segmental progeroid syndromes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2937005A1 (en) * | 2005-03-22 | 2006-09-28 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
| IL177989A0 (en) * | 2006-09-10 | 2006-12-31 | Yeda Res & Dev | Use of transcription factor inhibitor in the manufacture of a medicament |
| WO2008148016A1 (en) * | 2007-05-25 | 2008-12-04 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Inhibiting the signs of aging by inhibiting nf-kappa b activation |
| FR2926020B1 (fr) * | 2008-01-03 | 2010-08-13 | Univ Aix Marseille Ii | Composition cosmetique et/ou dermatologique |
| WO2011076880A1 (en) * | 2009-12-22 | 2011-06-30 | Emma Eriksson | Methods and use related to humanin and humanin-like peptides |
| US20140161785A1 (en) * | 2012-12-10 | 2014-06-12 | Feiyan Liu | Verticillin A Inhibition of Histone Methyltransferases |
-
2016
- 2016-01-14 ES ES16700619T patent/ES2764452T3/es active Active
- 2016-01-14 DK DK16700619.6T patent/DK3244909T3/da active
- 2016-01-14 EP EP16700619.6A patent/EP3244909B1/en active Active
- 2016-01-14 US US15/543,196 patent/US20170368134A1/en not_active Abandoned
- 2016-01-14 PT PT167006196T patent/PT3244909T/pt unknown
- 2016-01-14 HU HUE16700619A patent/HUE047603T2/hu unknown
- 2016-01-14 WO PCT/EP2016/050678 patent/WO2016113357A1/en not_active Ceased
- 2016-01-14 JP JP2017535453A patent/JP2018503632A/ja active Pending
- 2016-01-14 AU AU2016208001A patent/AU2016208001B2/en not_active Ceased
- 2016-01-14 SG SG11201705108TA patent/SG11201705108TA/en unknown
- 2016-01-14 BR BR112017015059-0A patent/BR112017015059A2/pt not_active IP Right Cessation
- 2016-01-14 PL PL16700619T patent/PL3244909T3/pl unknown
- 2016-01-14 CA CA2972740A patent/CA2972740A1/en not_active Abandoned
- 2016-01-14 CN CN201680005810.3A patent/CN107405378B/zh not_active Expired - Fee Related
-
2019
- 2019-12-27 CY CY20191101357T patent/CY1122583T1/el unknown
-
2020
- 2020-03-31 JP JP2020063619A patent/JP2020121980A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016113357A1 (en) | 2016-07-21 |
| JP2018503632A (ja) | 2018-02-08 |
| EP3244909A1 (en) | 2017-11-22 |
| PT3244909T (pt) | 2020-01-15 |
| HUE047603T2 (hu) | 2020-04-28 |
| AU2016208001A1 (en) | 2017-07-13 |
| CA2972740A1 (en) | 2016-07-21 |
| PL3244909T3 (pl) | 2020-04-30 |
| WO2016113357A8 (en) | 2017-09-08 |
| JP2020121980A (ja) | 2020-08-13 |
| US20170368134A1 (en) | 2017-12-28 |
| ES2764452T3 (es) | 2020-06-03 |
| SG11201705108TA (en) | 2017-07-28 |
| CY1122583T1 (el) | 2021-01-27 |
| AU2016208001B2 (en) | 2021-05-13 |
| BR112017015059A2 (pt) | 2019-05-14 |
| EP3244909B1 (en) | 2019-10-09 |
| CN107405378A (zh) | 2017-11-28 |
| CN107405378B (zh) | 2021-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3244909T3 (da) | Proteasominhibitorer til at behandle en lidelse relateret til en akkumulering af ikke-degraderet unormalt protein eller en cancer | |
| IL263586B (en) | Inhibitors of the menin-mll interaction | |
| EP3377059A4 (en) | INHIBITORS OF CXCR2 | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| DK3371171T3 (da) | Inhibitorer af RET | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| MA44474A (fr) | Nouveaux inhibiteurs de la ferroportine | |
| HUE052106T2 (hu) | Eljárás rák kezelésére | |
| DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
| DK3256594T3 (da) | Forbedret fremføring af viruspartikler til striatum og cortex | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3244891T3 (da) | Forbindelser til forbedring af mrna-splejsning | |
| DK3331876T3 (da) | Modulators of ror-gamma | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| IL254779A0 (en) | Methods of administering glutaminase inhibitors | |
| DK3368683T3 (da) | Fremgangsmåde til kvantifikationen af pd-l1 | |
| EP3313828A4 (en) | METALLO-BETA-Lactamase INHIBITORS | |
| DK3397648T3 (da) | Fremgangsmåde til deacetylering af biopolymerer | |
| DK3371165T3 (da) | Btk-inhibitor til anvendelse til behandling af kræft | |
| DK3261726T3 (da) | Sammensætning til behandling af acne | |
| DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| DK3283210T3 (da) | Fremgangsmåde | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności |